Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Masaya Orita"'
Autor:
Ryunosuke Yoshino, Nobuaki Yasuo, Yohsuke Hagiwara, Takashi Ishida, Daniel Ken Inaoka, Yasushi Amano, Yukihiro Tateishi, Kazuki Ohno, Ichiji Namatame, Tatsuya Niimi, Masaya Orita, Kiyoshi Kita, Yutaka Akiyama, Masakazu Sekijima
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Abstract Chagas disease results from infection by Trypanosoma cruzi and is a neglected tropical disease (NTD). Although some treatment drugs are available, their use is associated with severe problems, including adverse effects and limited effectiven
Externí odkaz:
https://doaj.org/article/9864fe2ce67f43499bde2b3251ec52d6
Autor:
Ryunosuke Yoshino, Nobuaki Yasuo, Daniel Ken Inaoka, Yohsuke Hagiwara, Kazuki Ohno, Masaya Orita, Masayuki Inoue, Tomoo Shiba, Shigeharu Harada, Teruki Honma, Emmanuel Oluwadare Balogun, Josmar Rodrigues da Rocha, Carlos Alberto Montanari, Kiyoshi Kita, Masakazu Sekijima
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0125829 (2015)
Chagas disease, caused by the parasite Trypanosoma cruzi, is a neglected tropical disease that causes severe human health problems. To develop a new chemotherapeutic agent for the treatment of Chagas disease, we predicted a pharmacophore model for T.
Externí odkaz:
https://doaj.org/article/4b0bac0f018a4bb7a714642595f2c480
Autor:
Daniel Ken Inaoka, Masakazu Sekijima, Takashi Ishida, Yutaka Akiyama, Masaya Orita, Kiyoshi Kita, Yukihiro Tateishi, Ryunosuke Yoshino, Tatsuya Niimi, Yohsuke Hagiwara, Kazuki Ohno, Ichiji Namatame, Yasushi Amano, Nobuaki Yasuo
Background Chagas disease is caused by the parasite Trypanosoma cruzi and is one of the neglected tropical diseases. Although two types of drugs are currently available, new drugs are still required because they have serious side effects. To develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69cd2fda5448f2fe1c6d1d106de6a02a
https://doi.org/10.26434/chemrxiv-2021-qk2ns
https://doi.org/10.26434/chemrxiv-2021-qk2ns
Autor:
Yukihiro Tateishi, Daniel Ken Inaoka, Kiyoshi Kita, Takashi Ishida, Yutaka Akiyama, Ichiji Namatame, Kazuki Ohno, Tatsuya Niimi, Yohsuke Hagiwara, Masakazu Sekijima, Masaya Orita, Ryunosuke Yoshino, Nobuaki Yasuo, Yasushi Amano
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Scientific Reports
Scientific Reports
Chagas disease results from infection by Trypanosoma cruzi and is a neglected tropical disease (NTD). Although some treatment drugs are available, their use is associated with severe problems, including adverse effects and limited effectiveness durin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a35262932be66ac297e0870fd3f8b4f
http://t2r2.star.titech.ac.jp/cgi-bin/publicationinfo.cgi?q_publication_content_number=CTT100756184
http://t2r2.star.titech.ac.jp/cgi-bin/publicationinfo.cgi?q_publication_content_number=CTT100756184
Publikováno v:
Journal of Chemometrics. 28:844-850
The quantification of both the impact and quality of a scientist's publication record is an essential step in making decisions concerning hiring, promotion, and allocation of funding. In an attempt to resolve this problem, Hirsh proposed the “h-ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d18a83bcf242c68ebc5c5fb0002a8cb
https://doi.org/10.1002/cem.2658
https://doi.org/10.1002/cem.2658
Autor:
Eiji Kurosaki, Masanao Sanagi, Hiroyuki Okumura, Hiroaki Masuzaki, Katsuhiko Gato, Kazuya Honbou, Akira Suwa, Takako Yonemoto, Tomohiko Yamaguchi, Yuko Kawasaki, Yuichi Tomura, Hirotoshi Kakuta, Tatsuya Niimi, Masaya Orita
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 349:10-20
A proportion of angiotensin II type 1 receptor blockers (ARBs) improves glucose dyshomeostasis and insulin resistance in a clinical setting. Of these ARBs, telmisartan has the unique property of being a partial agonist for peroxisome proliferator-act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::321fb2363212fdae6a21d1505fcdfa4d
https://doi.org/10.1124/jpet.113.211722
https://doi.org/10.1124/jpet.113.211722
Publikováno v:
Biological and Pharmaceutical Bulletin. 37:31-36
Nicotinamide phosphoribosyl transferase (NAMPT) is a key enzyme in the salvage pathway of mammalian nicotinamide adenine dinucleotide (NAD) biosynthesis, catalyzing the synthesis of nicotinamide mononucleotide from nicotinamide (Nam). The diverse fun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64f1d07f0a0e3b3e8744ac36424c931b
https://doi.org/10.1248/bpb.b13-00495
https://doi.org/10.1248/bpb.b13-00495
Autor:
Toshio Endo, Masaya Orita, Kazuki Ohno, Yohsuke Hagiwara, Ryota Koga, Masakazu Sekijima, Yutaka Akiyama
Publikováno v:
Curr Comput Aided Drug Des. 2013. 9(No. 3):396-401
The growing power of central processing units (CPU) has made it possible to use quantum mechanical (QM) calculations for in silico drug discovery. However, limited CPU power makes large-scale in silico screening such as virtual screening with QM calc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9a7c6f84b8c48a1cbf9d68eee845940
http://t2r2.star.titech.ac.jp/cgi-bin/publicationinfo.cgi?q_publication_content_number=CTT100665992
http://t2r2.star.titech.ac.jp/cgi-bin/publicationinfo.cgi?q_publication_content_number=CTT100665992
Autor:
Masaya Orita, Yosuke Hagiwara, Kazuki Ohno, Kazuhisa Tsunoyama, Ayako Moritomo, Toshihiro Watanabe
Publikováno v:
Expert Opinion on Drug Discovery. 8:1-5
The ever-increasing rate of drug discovery data has complicated data analysis and potentially compromised data quality due to factors such as data handling errors. Parallel to this concern is the rise in blatant scientific misconduct. Combined, these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::451a4e349fc8c647fe5de9e61892ad2e
https://doi.org/10.1517/17460441.2013.740007
https://doi.org/10.1517/17460441.2013.740007
Autor:
Hirotoshi Kakuta, Masatsugu Horiuchi, Yutaka Mori, Kazuki Ohno, Jitsuo Higaki, Masaya Orita, Tatsuya Niimi, Yasushi Amano, Ryuichi Morishita, Sho-ichi Yamagishi, Keiji Miyata, Issei Komuro, Shoji Takakura, Hitoshi Sakashita, Shokei Kim-Mitsuyama, Makoto Takeuchi
Publikováno v:
Biochemical and Biophysical Research Communications. 404:434-437
Angiotensin II type 1 receptor (AT1 receptor) blockers (ARBs) are one of the most popular anti-hypertensive agents. Control of blood pressure (BP) by ARBs is now a therapeutic target for the organ protection in patients with hypertension. Recent meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd2fc373009642821ad7d316707f1781
https://doi.org/10.1016/j.bbrc.2010.11.139
https://doi.org/10.1016/j.bbrc.2010.11.139